Integrative analysis of response to tamoxifen treatment in ER-positive breast cancer using GWAS information and transcription profiling

Breast Cancer: Basic and Clinical Research

Volumn 6, Issue 1, 2012, Pages 47-66

  Hicks, Chindo ^a   Kumar, Ranjit ^a   Pannuti, Antonio ^a   Miele, Lucio ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Tamoxifen genome wide association studies gene expression

Indexed keywords

ESTROGEN RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53; TAMOXIFEN;

APEX1 GENE; APOPTOSIS; ARTICLE; BLM GENE; BREAST CANCER; BTNL8 GENE; C1ORF38 GENE; CANCER PATIENT; CASP8 GENE; CDC37L1 GENE; CDKN2A GENE; CELL CYCLE; COL1A1 GENE; CONTROLLED STUDY; CSFT1 GENE; DCLREIC GENE; DMBT1 GENE; DNA DAMAGE; DNA REPAIR; DOWN REGULATION; DRUG RESPONSE; ECHDC1 GENE; EHMT2 GENE; ERCC5 GENE; ESR1 GENE; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GRIK1 GENE; HUMAN; ICAM1 GENE; IGF1R GENE; LSP1 GENE; MAJOR CLINICAL STUDY; MAP3K1 GENE; MGMT GENE; MMP8 GENE; MSH2 GENE; MSH6 GENE; PPP2R2B GENE; PREDICTION; PRKDC GENE; RAD51L1 GENE; RB1 GENE; RELN GENE; RISK FACTOR; RPA GENE; RPA2 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SKAP2 GENE; SLC4A7 GENE; SOD2 GENE; SORBS1 GENE; TGFB1 GENE; TOX3 GENE; TRIM45 GENE; TUMOR GENE; UPREGULATION; WWOX GENE; XPA GENE; XRCC5 GENE;

EID: 84863408216     PISSN: None     EISSN: 11782234     Source Type: Journal    
DOI: 10.4137/BCBCR.S8652     Document Type: Article

References (45)

1. American Cancer Society. Breast cancer facts and figures 2010. Atlanta American Cancer Society. 2010.
2. Early breast cancer trials' collaborative group (EBCTCG). Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet. 1998;351: 1451-67.
3. Ingle JN. Pharmacogenetics and pharmacogenomics of endocrine agents for breast cancer. Breast Cancer Res. 2008;10(Suppl 4):S17.
4. Fisher B, Constantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have extrogen-receptor-positive tumors. N Engl J Med. 1989; 320:479-84.
5. Fisher B, Jeong JH, Bryant J, et al. Treatment of lymph-node-negative, estrogen-receptor-positive breast cancer: long-term findings from the National surgical adjuvant breast and bowel project randomized clinical trials. Lancet. 2004;364:858-68.
6. Jansen MPHM, Foekens JA, van Staveren IL, et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol. 2005;23:732-40.
7. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New Eng J Med. 2004;351: 2817-26.
8. Symmans WF, Hatzis C, Sotiriou C, Andre F, et al. Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol. 2010;28: 4111-9.
9. Mendes-Pereira AM, Sims D, Dexter T, et al. Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen. Proc Natl Acad U S A. 2011.
10. Hicks C, Pannuti A, Miele L. Association of GWAS information with the Notch signaling pathway. Cancer Informatics. 2011.
11. Hicks C, Asfour R, Pannuti A, Miele L. An integrative genomics approach to biomarker discovery in breast cancer. Cancer Informatics. 2011.
12. Sotiriou C, Wirapati P, Loi S, et al. Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. J Nat Cancer Inst. 2006;98:262-72.
13. Microarray Analysis Suite 5.0, Affymetrix Inc. Santa Clara, California.
14. Berger JA, Hautaniemi S, Jarvinen A-K, Edgren H, Mitra SK, Astola J. Optimized lowess normalization parameter selection for DNA microarray data. BMC Bioinformatics. 2004;5:194.
15. Benjamini Y, Hochberg Yosef. Controlling the false discovery rat: a practical and powerful approach to multiple testing. J Royal Stat Society. Series B Methodology. 1995;57(1):289-300.
16. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Nat Acad Sci U S A. 1998; 95:14863-8.
17. Morrissey ER, Diaz-Uriarte R. Pomello II: Finding differentially expressed genes. Nucl Acids Res. 2009;37:W581-6.
18. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P. GenePattern 2.0. Nature Genetics. 2006;38(5):500-1.
19. SAS statistical System. SAS Cary, NC.
20. Giamas G, Filipova A, Jacob J, et al. Kinome screening for regulators of the estrogen receptor identifies LMTK3 as new therapeutic target in breast cancer. Nature Med. 2011;17(6):715-9.
21. Maraqa L, Cummings M, Peter MB, et al. Carcinoembryonic antigen cell adhesion molecule 6 predicts breast cancer recurrence following adjuvant tamoxifen. Clin Cancer Res. 2008;14(13):4355-6.
22. Bostner J, Waltersson MA, Fornander T, et al. Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in post menopausal breast cancer. Oncogene. 2007;26:6997-7005.
23. Vendrell JA, Ghayad S, Ben-Larbi S, et al. A20/TNFAIP3, a new estrogenregulated gene that confers tamoxifen resistance in breast cancer cells. Oncogene. 2007;26:4656-67.
24. Shoman N, Klassen S, McFadden A, et al. Reduced PTEN expression predicts relapse in patients with breast cancer treated tamoxifen. Modern Pathology. 2005;18:250-9.
25. Hurtado A, Holmes KA, Geistlinger TR, et al. Regulation of ERBB2 by oestrogen receptor-PAX2 determine response to tamoxifen. Nature. 2008; 456:663-67.
26. Ingenuity System. Ingenuity Inc. California.
27. Gene Ontology Consortium. Creating the gene ontology resource: Design and implementation. Genome Res. 2001;11:1425-33.
28. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999;286:487-91.
29. Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets and side effects. New Eng J Med. 2003;348:538-49.
30. Musgrove EA, Sergio CM, Loi S, Inman CK, Anderson LR, et al. Identification of functional networks of estrogen-and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer. PLoS one. 2008;3(8):e2987.
31. Mandlekar S, Kong A-NT. Mechanisms of tamoxifen-induced apoptosis. Apoptosis. 2001;6:469-77.
32. Zhou Y, Eppenberger-Castori S, Eppenberger U, Benz CC. The NFkB pathway and endocrine-resistant breast cancer. Endocrine-Related Cancer. 2005;12:S37-46.
33. Elledge RM, Green S, Howes L, Clark GM, et al. bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: A south-west oncology group study. J Clin Oncol. 1997;15(5):1916-22.
34. Berns EMJJ, Klijn JGM, van Putten WLJ, et al. P53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer. J Clin Oncol. 1998;16(1):121-7.
35. Poplawski T, Zadrozny M, Kolacinska A, et al. Polymorphisms of the DNA mismatch repair gene HMSH2 in breast cancer occurence and progression. Breast Cancer Res Treatment. 2005;94:199-204.
36. Crowley JJ, Sullivan PF, McLeod HL. Pharmacogenomic of genome-wide association studies: lessons learned thus far. Pharmacogenomics. 2009;10(2): 161-3.
37. Yan H, Yuan W, Velculescu VE, et al. Allelic variation in gene expression. Science. 2002;297:1143.
38. Buckland PR. Allele-specific gene expression differences in humans. Human Mol Genet. 2004;13(2):R255-60.
39. Meyer KB, Maia A, O'Reilly M, et al. Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biology. 2008;6(5):e108.
40. Roses AD. Pharmacogenetics and drug development: the path to safer and more effective drugs. Nature Reviews Genetics. 2004;5:645-56.
41. Haiman CA, Hsu C, de Bakker PIW, et al. Comprehensive association testing of common genetic variation in DNA repair pathway genes in relationship with breast cancer risk in multiple populations. Hum Mol Genet. 2008;17(6):825-34.
42. Menashe I, Maeder D, Garcia-Closas M, et al. Pathway analysis of breast cancer genome-wide association study highlights three pathways and one canonical signaling cascade. Cancer Res. 2010;7(11):4453-9.
43. Manounas EP, Tang G, Fisher B, et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: Results from NSABP B-14 and NSABP B-20. J Clin Oncol. 2010;28(10):1677-83.
44. Kelly CM, Krishnamurthy S, Bianchini G, et al. Utility of Oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. Cancer. 2010; 116(22):5161-7.
45. Helgadottir A, Manolescu A, Helgason A, et al. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet. 2006;38:68-74.